Heeringa et al., 1998 - Google Patents
Expression of iNOS, eNOS, and peroxynitrite-modified proteins in experimental anti-myeloperoxidase associated crescentic glomerulonephritisHeeringa et al., 1998
View PDF- Document ID
- 7816691642252602651
- Author
- Heeringa P
- van Goor H
- Moshage H
- Klok P
- Huitema M
- de Jager A
- Schep A
- Kallenberg C
- Publication year
- Publication venue
- Kidney international
External Links
Snippet
Expression of iNOS, eNOS and peroxynitrite-modified proteins in experimental anti-MPO associated necrotizing crescentic glomerulonephritis. Nitric oxide radicals are recognized as important mediators in various physiological and pathophysiological processes. During …
- 206010018378 Glomerulonephritis rapidly progressive 0 title abstract description 13
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Heeringa et al. | Expression of iNOS, eNOS, and peroxynitrite-modified proteins in experimental anti-myeloperoxidase associated crescentic glomerulonephritis | |
| Bakker et al. | Blood-brain barrier permeability during Cuprizone-induced demyelination: Implications for the pathogenesis of immune-mediated demyelinating diseases | |
| Seya et al. | Quanatitative analysis of membrane cofactor protein (MCP) of complement: High expression of MCP on human leukemia cell lines, which is down-regulated during cell-differentiation | |
| Passwell et al. | Local extrahepatic expression of complement genes C3, factor B, C2, and C4 is increased in murine lupus nephritis. | |
| Poelstra et al. | Intraglomerular platelet aggregation and experimental glomerulonephritis | |
| ES2632625T3 (en) | Composition for use in the treatment of a disease | |
| Matsuo et al. | Glomerulonephritis induced in the rabbit by antiendothelial antibodies. | |
| Jansen et al. | In situ complement activation in porcine membranoproliferative glomerulonephritis type II | |
| US20030086929A1 (en) | Treatment of prostate cancer by inhibitors of ATP synthase | |
| US20070065433A1 (en) | Methods and compositions for the treatment of meconium aspiration syndrome | |
| US6153195A (en) | Method of delivering drugs to cells specific for an HL-60 lectin | |
| IBRAHIM et al. | Reproductive tract secretions and bull spermatozoa contain different clusterin isoforms that cluster cells and inhibit complement‐induced cytolysis | |
| DE69331100T2 (en) | USE OF P97 IN DIAGNOSIS OF MORBUS ALZHEIMER | |
| DE69431167T2 (en) | METHOD FOR SELECTIVE METHIONINE DRAWNING FOR MALIGNE MAMMAL CELLS | |
| Miyamoto et al. | Immunohistochemical study of the membrane attack complex of complement in IgA nephropathy | |
| WO2005117848A9 (en) | Vascular targets for detecting, imaging and treating neoplasia or neovasculature | |
| Scherberich et al. | Glomerular and tubular membrane antigens reflecting cellular adaptation in human renal failure. | |
| CA2758829C (en) | Method of treating demyelinating disease | |
| van Kleef et al. | In vitro and in vivo expression of endothelial von Willebrand factor and leukocyte accumulation after fractionated irradiation | |
| Quigg et al. | Studies with antibodies to cultured rat glomerular epithelial cells. Subepithelial immune deposit formation after in vivo injection | |
| Redline et al. | Defective anti-listerial responses in deciduoma of pseudopregnant mice | |
| Van Dixhoorn et al. | Characterization of complement C6 deficiency in a PVG/c rat strain | |
| WO1999049865A1 (en) | Use of platelet activating factor (paf) inhibitors to inhibit il-5 induced eosinophil activation or degranulation | |
| Davin et al. | Urinary excretion of neutral proteinases in nephrotic rats with a glomerular disease | |
| Bazin et al. | The metabolism of different immunoglobulin classes in irradiated mice: V. Contribution of the gut to serum IgA levels in normal and irradiated mice |